TriSalus Life Sciences (NASDAQ:TLSI) CEO Mary Szela Sells 4,358 Shares

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary Szela sold 4,358 shares of the firm’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $4.13, for a total transaction of $17,998.54. Following the completion of the transaction, the chief executive officer directly owned 768,931 shares of the company’s stock, valued at $3,175,685.03. This represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

TriSalus Life Sciences Trading Up 1.8%

NASDAQ TLSI opened at $3.93 on Friday. The firm’s fifty day moving average price is $4.91 and its two-hundred day moving average price is $5.29. TriSalus Life Sciences, Inc. has a 1 year low of $3.42 and a 1 year high of $7.95. The firm has a market capitalization of $240.95 million, a P/E ratio of -2.15 and a beta of 0.42.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The firm had revenue of $13.21 million during the quarter, compared to analyst estimates of $13.20 million. On average, research analysts anticipate that TriSalus Life Sciences, Inc. will post -1.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC raised its holdings in TriSalus Life Sciences by 1.5% in the 4th quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock valued at $14,454,000 after acquiring an additional 30,582 shares during the period. AWM Investment Company Inc. acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $6,812,000. Vanguard Group Inc. grew its holdings in TriSalus Life Sciences by 42.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after buying an additional 345,186 shares in the last quarter. Gilder Gagnon Howe & Co. LLC grew its holdings in TriSalus Life Sciences by 32.1% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after buying an additional 265,618 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in TriSalus Life Sciences by 35.5% during the 4th quarter. Geode Capital Management LLC now owns 751,207 shares of the company’s stock worth $5,245,000 after buying an additional 196,752 shares during the period. Institutional investors and hedge funds own 2.58% of the company’s stock.

Trending Headlines about TriSalus Life Sciences

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: TriSalus reported a slight quarterly earnings beat on March 5 (EPS -$0.12 vs. consensus -$0.13) with revenue roughly in line with expectations — this gives a fundamental rationale for buying interest. MarketBeat TLSI Summary
• Neutral Sentiment: Trading volume was elevated (≈396k shares vs. ~181k average), suggesting the market is actively re-pricing the name; price remains below the 50-day ($4.95) and 200-day ($5.30) moving averages, a neutral-to-cautious technical backdrop.
• Negative Sentiment: CEO Mary T. Szela sold 15,944 shares on March 17 at an average $3.85 (≈$61.4k) and previously sold 4,358 shares on March 11 at $4.13; these transactions reduced her ownership by ~2.07% and ~0.56% respectively — a notable insider reduction. CEO Form 4
• Negative Sentiment: Other officers also reported multiple small sales this week: Richard Marshak (several sales on Mar 11–16). These are modest in dollar terms but collectively add to negative insider-sentiment signals. Marshak Form 4
• Negative Sentiment: Insider sales by Bryan F. Cox (multiple small sales Mar 11–16) and Jodi Devlin (multiple small sales Mar 11–16) were also disclosed, further contributing to the selling narrative. Cox Form 4 Devlin Form 4

Wall Street Analysts Forecast Growth

Several analysts have issued reports on TLSI shares. Canaccord Genuity Group dropped their price objective on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Zacks Research upgraded TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. Finally, Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, TriSalus Life Sciences currently has an average rating of “Hold” and an average target price of $7.00.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.